GlassScriptPhysician profile
Jeremy W Cook
NPI 1982865317
$1,331.56
in general payments reported to CMS, 2019-2025
30 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $59.08 · 2022: $187 · 2023: $287 · 2024: $381 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $155.39 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $127.41 | 2019-2025 | Dupixent |
| Incyte Corporation | $105.13 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $75.53 | 2023-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $69.69 | 2019-2024 | Winlevi, Odomzo |
| Lilly USA, LLC | $67.37 | 2019-2025 | Ebglyss, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.29 | 2023-2025 | Spevigo |
| Pfizer INC. | $65.07 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.03 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $56.92 | 2024-2025 | Adbry, Anzupgo |
| Amgen INC. | $54.34 | 2023-2025 | Otezla, Otezla |
| Revance Therapeutics, INC. | $51.68 | 2024 | Daxxify |
| Dermira, INC. | $40.17 | 2019-2020 | |
| Kyowa Kirin, INC. | $31.28 | 2025 | |
| Genzyme Corporation | $31.10 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $30.87 | 2022 | |
| Celgene Corporation | $29.18 | 2019 | |
| Galderma Laboratories, L.P. | $26.39 | 2019-2023 | Aklief |
| Mimedx Group, INC. | $20.97 | 2024 | |
| Verrica Pharmaceuticals INC. | $18.86 | 2024 | Ycanth |
| Novartis Pharmaceuticals Corporation | $17.66 | 2023 | |
| Dermavant Sciences, INC. | $16.64 | 2022 | |
| Arcutis Biotherapeutics, INC. | $16.64 | 2025 | Zoryve |
| Abbvie INC. | $16.46 | 2022 | |
| Genentech USA, INC. | $15.43 | 2022 | |
| Prugen, INC. Pharmaceuticals | $14.84 | 2019 | |
| Sandoz INC. | $14.77 | 2023 | Hyrimoz |
| Smith+Nephew, INC. | $13.54 | 2024 | Collagenase Santyl |
| Promius Pharma LLC | $12.73 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.